NEW YORK, NY / ACCESSWIRE / September 20, 2017 / Traders can hardly wait for Capricor Therapeutics to release six-month follow-up data from its Hope-Duchenne clinical trial of CAP-1002. Shares skyrocketed on Tuesday after the company announced on Monday that it would be presenting the results on October 4th. Shares of Supernus weren't so lucky however and dropped significantly after announcing a change to a drug study of SPN-810.

RDI Initiates Coverage on:

Capricor Therapeutics, Inc.
http://www.rdinvesting.com/report/?ticker=CAPR

Supernus Pharmaceuticals, Inc.
http://www.rdinvesting.com/report/?ticker=SUPN

Capricor Therapeutics' shares exploded on Tuesday and closed the day up 70.45% on tremendous volume compared to usual. Trading volume yesterday was around 33 million shares compared to an average of just under 1.5 million shares. Earlier in the week the clinical-stage biotechnology company announced that it would be presenting six-month follow-up results from the randomized Phase I/II HOPE-Duchenne clinical trial of CAP-1002 in boys and young men with Duchenne muscular dystrophy (DMD) at the 22nd International Congress of the World Muscle Society on October 4th.

Access RDI's Capricor Therapeutics, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=CAPR

Supernus Pharmaceuticals' shares tumbled on Tuesday, closing in the red down 23.36%. The stock was one of the biggest decliners on the NASDAQ after the company announced that it has decided to make a drug study change. Supernus decided to stop evaluating the lower dose option of its pipeline candidate, SPN-810, in two phase III clinical trials. SPN-810 is a drug that is intended to treat impulsive aggression in children from ages 6 to 12 who have attention deficit hyperactivity disorder. The company has decided to stop evaluating the 18mg option of the drug but will continue to evaluate the 36 mg dose in the studies. The company stated, "Moving forward, all patients will be randomized to either the 36 mg dose arm or placebo until the predetermined total number of patients are enrolled without changing the size of the trials." The company said it "believes that this will maximize the probability of reaching a statistically significant outcome for the 36 mg dose."

Access RDI's Supernus Pharmaceuticals, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=SUPN

Our Actionable Research on Capricor Therapeutics, Inc. (NASDAQ: CAPR) and Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com